ALEXANDRIA, Va. – CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO) that oversees the development and operation of CancerLinQ®, a health information technology platform working to improve quality and value of care for all patients by connecting cancer care team members, researchers, and sponsors with real-world cancer data. In addition, CancerLinQ and Integra Connect have entered into an agreement to collaborate on products and services geared toward improving the quality of cancer care and the access of the CancerLinQ® platform to oncology practices.
“This certification and collaboration with Integra represents progress in our efforts to seamlessly transfer oncology-related data and deliver it to practices in the CancerLinQ network,” said CancerLinQ LLC Chief Executive Officer Cory Wiegert. “We look forward to working with Integra and other EHR systems as we try to fulfill our ultimate goal of virtually learning from every patient with cancer.”
CancerLinQ LLC launched the CancerLinQ® Certified EHR program to recognize systems that meet specific requirements for interoperability and cancer data standardization. To become a CancerLinQ® Certified EHR and maintain this status, an EHR system must do the following, among satisfying other initial and ongoing criteria:
- Support the creation and maintenance of health records including, but not limited to, individually identifiable oncology and/or hematology patient information;
- Maintain a leading industry standard for the recording of precise, structured, and standardized clinical data;
- Meet certain federal standards for EHR technology, interoperability, privacy, and safety;
- Work to achieve the continuous, secure transfer of data to the CancerLinQ® system from patients associated with practices that both participate in CancerLinQ and use the EHR; and
- Participate in efforts among stakeholders in the cancer community to drive improvement of interoperability, establish core data elements, and support efforts to standardize and harmonize data approaches.
Integra Connect delivers a comprehensive, integrated suite of cloud-based technologies and services that enable community oncologists to optimize clinical and financial performance as reimbursement shifts to value-based models and precision medicine. In addition to Integra Connect’s EHR Solution for Oncology being designated as a CancerLinQ® Certified EHR, the two entities are exploring ways to increase health information technology interoperability and provide valuable tools to oncology practices to improve and personalize care for their patients.
This new effort aims to provide all CancerLinQ subscribing practices who use Integra Connect with more streamlined access to the CancerLinQ® platform, where they will be able to view and analyze relevant data for their patients. In addition, CancerLinQ and Integra Connect will work together to develop dashboards within the CancerLinQ platform, allowing all CancerLinQ subscribing practices to use additional tools to analyze patients’ health data.
“This collaboration will bring the power of data analytics into the offices and exam rooms of more oncologists,” said Charles Saunders, MD, CEO of Integra Connect. “The new analytic tools we’re working to develop will provide critical resources for oncologists, so they can improve the day-to-day care of their patients.”
For more information on how to participate or apply for EHR certification, please visit CancerLinQ.org.
CancerLinQ® is supported in part through Conquer Cancer®, The ASCO foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD and Susan M. DaSilva; and Susan G. Komen®.
CancerLinQ® and CancerLinQ Discovery® are projects of CancerLinQ LLC.
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.
About CancerLinQ LLC
CancerLinQ LLC is a subsidiary of American Society of Clinical Oncology, Inc. established for the development and operation of the CancerLinQ® initiative. CancerLinQ® is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit www.cancerlinq.org.
About Integra Connect
Integra Connect delivers a comprehensive, integrated suite of cloud-based technologies and services that enable specialty groups to optimize clinical and financial performance as reimbursement shifts to value-based models. Connected by the IntegraCloud platform, the company’s core applications span population health including care management; advanced analytics; registry and regulatory reporting; specialty-specific EHR; practice management; and revenue cycle management. All are designed to help specialty practices transform operationally in adherence with complex regulations, including MACRA program requirements. Integra Connect partners with large groups in the U.S. focused on oncology and urology, as well as with other key healthcare constituents, including emergency medical services firms, hospitalist groups and life sciences companies.